disulfiram has been researched along with Angiogenesis, Pathologic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Roy, B | 1 |
| Palaniyandi, SS | 1 |
| Cvek, B | 1 |
| Shian, SG | 1 |
| Kao, YR | 1 |
| Wu, FY | 1 |
| Wu, CW | 1 |
| Brar, SS | 1 |
| Grigg, C | 1 |
| Wilson, KS | 1 |
| Holder, WD | 1 |
| Dreau, D | 1 |
| Austin, C | 1 |
| Foster, M | 1 |
| Ghio, AJ | 1 |
| Whorton, AR | 1 |
| Stowell, GW | 1 |
| Whittall, LB | 1 |
| Whittle, RR | 1 |
| White, DP | 1 |
| Kennedy, TP | 1 |
| Hannan, GN | 1 |
| McAuslan, BR | 1 |
| Marikovsky, M | 1 |
| Nevo, N | 1 |
| Vadai, E | 1 |
| Harris-Cerruti, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| DIRECT (DIsulfiram REsponse as add-on to ChemoTherapy in Recurrent) Glioblastoma: A Randomized Controlled Trial[NCT02678975] | Phase 2/Phase 3 | 88 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer[NCT03323346] | Phase 2 | 150 participants (Anticipated) | Interventional | 2017-09-29 | Recruiting | ||
| Randomized Phase 2 Trial of Treatment of Advanced Non Small Cell Lung Carcinoma With/Without Disulfiram and Cisplatin Navelbine[NCT00312819] | Phase 2/Phase 3 | 60 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for disulfiram and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome.
Topics: Clinical Trials as Topic; Disulfiram; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; | 2011 |
5 other studies available for disulfiram and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Aldehyde dehydrogenase 2 inhibition potentiates 4-hydroxy-2-nonenal induced decrease in angiogenesis of coronary endothelial cells.
Topics: Aldehyde Dehydrogenase, Mitochondrial; Aldehydes; Animals; Cell Line; Cells, Cultured; Diabetic Card | 2020 |
Inhibition of invasion and angiogenesis by zinc-chelating agent disulfiram.
Topics: Animals; Chelating Agents; Chickens; Disulfiram; Humans; Matrix Metalloproteinase 2; Matrix Metallop | 2003 |
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Copper; Cyclic AMP Response El | 2004 |
Modulation of synthesis of specific proteins in endothelial cells by copper, cadmium, and disulfiram: an early response to an angiogenic inducer of cell migration.
Topics: Animals; Aorta; Cadmium; Cattle; Cell Line; Cell Movement; Clone Cells; Copper; Disulfiram; Endothel | 1982 |
Cu/Zn superoxide dismutase plays a role in angiogenesis.
Topics: Animals; Apoptosis; Brain Neoplasms; Carcinoma, Lewis Lung; Disulfiram; Endothelium, Vascular; Enzym | 2002 |